Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
PLoS One. 2021 Oct 1;16(10):e0258160. doi: 10.1371/journal.pone.0258160. eCollection 2021.
PLoS One. 2021.
PMID: 34597353
Free PMC article.